Gustave Roussy Cancer Campus-ko ikertzaileekin lankidetzan egindako argitalpenak (22)

2023

  1. Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial

    European Journal of Cancer, Vol. 184, pp. 48-59

2022

  1. A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors

    Molecular Cancer Therapeutics, Vol. 21, Núm. 4, pp. 625-634

  2. Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib

    npj Precision Oncology, Vol. 6, Núm. 1

2021

  1. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer

    New England Journal of Medicine, Vol. 385, Núm. 25, pp. 2336-2347

  2. Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study

    European Journal of Cancer, Vol. 151, pp. 49-62

  3. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial

    The Lancet Oncology, Vol. 21, Núm. 1, pp. 60-72

2019

  1. Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: Longitudinal analyses from the randomized phase III ExteNET trial

    Annals of Oncology, Vol. 30, Núm. 4, pp. 567-574

  2. IMpassion132 Phase III trial: Atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer

    Future Oncology, Vol. 15, Núm. 17, pp. 1951-1961

  3. PIK3CA alterations and benefit with neratinib: Analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

    Breast Cancer Research, Vol. 21, Núm. 1

2017

  1. A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4)

    Annals of Oncology, Vol. 28, Núm. 2, pp. 313-320

  2. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 18, Núm. 12, pp. 1688-1700

2016

  1. Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics

    European Journal of Cancer, Vol. 53, pp. 75-83

  2. Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer [Supportive Care in Cancer, (2015), DOI:10.1007/s00520-015-2904-5]

    Supportive Care in Cancer

  3. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 17, Núm. 3, pp. 367-377

  4. Phase 2 Study of Trabectedin in Patients With Hormone Receptor–Positive, HER-2–Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene

    Clinical Breast Cancer, Vol. 16, Núm. 5, pp. 364-371

  5. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

    Supportive Care in Cancer, Vol. 24, Núm. 1, pp. 447-455

2014

  1. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: Investigation in the QUASAR2 study, systematic review, and meta-analysis

    Journal of Clinical Oncology, Vol. 32, Núm. 10, pp. 1031-1039

2011

  1. Overview of preoperative radiochemotherapy in breast cancer: Past or future?

    Clinical and Translational Oncology, Vol. 13, Núm. 7, pp. 446-450

  2. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials

    The Lancet, Vol. 378, Núm. 9793, pp. 771-784